Allumia Ventures
About Allumia Ventures
Allumia Ventures is a healthcare venture capital firm based in the Seattle area. It began in 2015 as the venture arm of Providence and became an independent firm in January 2025, with Providence as its anchor investor.
The firm invests in digital health, tech-enabled healthcare services, and medtech. It focuses on commercial-stage companies using technology to solve the industry’s most pressing problems, targeting venture-class returns.
Its limited partner base includes health systems and other strategic healthcare organizations. This gives portfolio companies direct access to the stakeholders that drive adoption, shortening sales cycles, and the firm introduces its companies to this investor network throughout the year.
Portfolio companies include Omada Health, Lyra Health, DexCare, Kyruus, Xealth, Arrive Health, and Affect Therapeutics.
Allumia works with a select group of companies rather than a large portfolio, acting as a long-term partner through good and bad cycles. Its third fund is anchored by a $150 million commitment from Providence, with a target of $200 million to $250 million.
People
- Jennifer Lee, Vice President